New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting

- Studies Evaluated Improvement in Symptoms Both in the Short and Long Term - WILMINGTON, Del., May 5 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced new study data on SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for the treat...

Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting

...ue diagnostic hyperspace mapping technology. "We are pleased to present this clinically important blood test to the psychiatric community at the apa meeting," stated Stan Sewitch, President and CEO of Ridge. "We believe the assay results provide an objective adjunct to a patient's diagnosis and ma...

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

...s sponsored by Janssen-Cilag, Medical Affairs EMEA. Separately, an interim analysis from a two-year U.S. observational study also presented today at apa showed patients taking RLAI had significantly improved functioning within three months after starting treatment. That study enrolled 532 patients from...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

...extended release study findings to be presented at apa a relevant contribution to the growing body of res... with ADHD: Parental Impressions and Experiences apa Poster Presentation # NR6-025 May 8, 2008; 11:00...f Lisdexamfetamine Dimesylate in Adults with ADHD apa Oral Presentation Session # 28 Methylphenidate T...

Lilly Receives NCQA Design Certification for Depression Care Management Program

...atisfaction assessment and outcomes measurement; and provides a comprehensive list of MDD resources. The foundation of this program is based upon the apa Standards of Care for major depressive disorder, the HEDIS(R) measure for Antidepressant Medication Management, and several other related, peer-review...

New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia

...l needs. Additional information about Lilly is available at www.lilly.com . C-LLY (i) apa Practice Guidelines. Am J Psychiatry. 2004. (ii) Maguire GA. Am J Health Syst Pharm. 2002;59(17 suppl 5):S4-S11. (iii) Modestin J, Ammann...

Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting

..."The upcoming clinical research to be presented at apa reaffirms Shire's commitment to understanding the ...tive presentation sessions have taken place at the apa annual meeting. VYVANSE (lisdexamfetamine d...With Attention-Deficit/Hyperactivity Disorder apa Poster# NR739 May 23, 2007; 3:00 p.m. PDT (6...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

... Pooled Findings Presented at 2007 apa Meeting Also Showed No Significant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Findings f...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

... - Data Presented at 2007 apa Meeting - COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Data from four new studies examining safety and efficacy of desvenlafaxine succin...

BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference

... in schizophrenic patients is expected to begin in the end of June, 2007. "We are pleased to be presenting these promising results for BL-1020 at the apa Annual Meeting and look forward to the imminent initiation of the Phase II trial for this compound," commented Morris C. Laster, M.D., chief executive...

New Data Suggests Less Abuse-Related Effects For OROS Methylphenidate

...st ratio of DAWN abuse reports to prescribed use (14 x 10-6) ; Ciccone, P.E., Starr, H.L., Coleman, J.J., Mrazik, T., DuPont, R.L., Bensinger P.B., ). apa Poster Board Number NR526: OROS MPH(R): A Methylphenidate Formulation with a Low Potential for Abuse, 2007. (2) Kessler RC, Adler L, Barkley R, Bied...

Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting

... San Diego. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the apa meeting include the following abstracts: --NG2-73, a Novel GABA(A) Partial Agonist, Rapidly Induced Sleep in a Transient Insomnia Study (Phase 2a) ...

New Data Focuses on Abuse of Stimulant Medication

...st ratio of DAWN abuse reports to prescribed use (14 x 10-6) ; Ciccone, P.E., Starr, H.L., Coleman, J.J., Mrazik, T., DuPont, R.L., Bensinger P.B., ). apa Poster Board Number NR526: OROS MPH(r): A Methylphenidate Formulation with a Low Potential for Abuse, 2007. 2Kessler RC, Adler L, Barkley R, Biederm...